Nanomedicinal strategies to treat multidrug-resistant tumors: Current progress

Xiaowei Dong, Russell J. Mumper

Research output: Contribution to journalReview articlepeer-review

282 Scopus citations


Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. P-glycoprotein is an important and the best-known membrane transporter involved in MDR. Several strategies have been used to address MDR, especially P-glycoprotein-mediated drug resistance in tumors. However, clinical success has been limited, largely due to issues regarding lack of efficacy and/or safety. Nanoparticles have shown the ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-glycoprotein and the observed improved anticancer efficacy suggests that nanomedicinal strategies provide a new opportunity to overcome MDR. This article focuses on nanotechnology-based formulations and current nanomedicine approaches to address MDR in tumors and discusses the proposed mechanisms of action.

Original languageEnglish
Pages (from-to)597-615
Number of pages19
Issue number4
StatePublished - Jun 2010


  • Brij
  • Drug delivery
  • Efflux transporters
  • Lipid formulation
  • Nanoparticle
  • P-glycoprotein
  • Pluronic
  • Vitamin e tpgs


Dive into the research topics of 'Nanomedicinal strategies to treat multidrug-resistant tumors: Current progress'. Together they form a unique fingerprint.

Cite this